|
Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy. |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Genentech; Pfizer |
Speakers' Bureau - Astellas Medivation; Dendreon; Sanofi |
Research Funding - Aragon Pharmaceuticals (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Janssen |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune |
|
|
Employment - Kaiser Permanente |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Research Funding - Epic Sciences |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Leadership - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Patents, Royalties, Other Intellectual Property - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Genomic Health |
|
|
Employment - Epic Sciences |
Leadership - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Patents, Royalties, Other Intellectual Property - Patents Pending |
|
|
No Relationships to Disclose |